Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $139.3 million.

  • Altimmune's Liabilities and Shareholders Equity rose 47.74% to $218.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $705.4 million, marking a year-over-year decrease of 2.06%. This contributed to the annual value of $139.3 million for FY2024, which is 33.87% down from last year.
  • Altimmune's Liabilities and Shareholders Equity amounted to $139.3 million in FY2024, which was down 33.87% from $210.6 million recorded in FY2023.
  • Altimmune's Liabilities and Shareholders Equity's 5-year high stood at $245.1 million during FY2020, with a 5-year trough of $139.3 million in FY2024.
  • In the last 3 years, Altimmune's Liabilities and Shareholders Equity had a median value of $206.9 million in 2022 and averaged $185.6 million.
  • In the last 5 years, Altimmune's Liabilities and Shareholders Equity skyrocketed by 353.43% in 2020 and then tumbled by 33.87% in 2024.
  • Altimmune's Liabilities and Shareholders Equity (Yearly) stood at $245.1 million in 2020, then decreased by 10.71% to $218.9 million in 2021, then dropped by 5.45% to $206.9 million in 2022, then increased by 1.79% to $210.6 million in 2023, then plummeted by 33.87% to $139.3 million in 2024.